Current Report Filing (8-k)
23 Dezembro 2022 - 06:31PM
Edgar (US Regulatory)
0001260990false00012609902022-12-232022-12-23
```
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of report (Date of earliest event reported)
December 23, 2022
Oncternal Therapeutics, Inc.
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
|
Delaware
|
|
000-50549
|
|
62-1715807
|
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission File
Number)
|
|
(IRS Employer Identification No.)
|
|
|
|
|
12230 El Camino Real
Suite 230
San
Diego,
CA
92130
(858)
434-1113
|
|
|
(Address and zip code; telephone number, including area code, of
registrant’s principal executive offices)
N/A
(Former Name or Former Address, if Changed Since Last
Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see
General Instruction A.2. below):
|
|
|
☐
|
Written communication pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
|
|
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|
|
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the
Act:
|
|
|
|
|
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
|
Common Stock, par value $0.001 per share
|
|
ONCT
|
|
The Nasdaq Stock Market, LLC
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
On December 23, 2022, Jinzhu Chen, Ph.D. resigned from the Board of
Directors (the “Board”) of Oncternal Therapeutics, Inc.
(“Oncternal”). Dr. Chen’s resignation was not the result of any
disagreement on any matter relating to Oncternal’s operations,
policies or procedures.
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
Oncternal Therapeutics, Inc.
|
|
|
|
|
Date: December 23, 2022
|
By:
|
/s/ Richard G. Vincent
|
|
|
|
|
Name: Richard G. Vincent
|
|
|
|
|
Title: Chief Financial Officer
|
2
Oncternal Therapeutics (NASDAQ:ONCT)
Gráfico Histórico do Ativo
De Fev 2023 até Mar 2023
Oncternal Therapeutics (NASDAQ:ONCT)
Gráfico Histórico do Ativo
De Mar 2022 até Mar 2023
